Search 

• APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer and related conditions. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs around 25 people and is led by a management team with strong background in drug development, especially in cancer immune therapy.
• Apeiron has a portfolio of innovative projects, five of which are in clinical development. Its lead project APN311 is in an ongoing phase III trial in neuroblastoma, with more than half of the patients already recruited.

APIM Therapeutics AS is a preclinical biotech company developing novel peptide anti-cancer drugs for various oncology indications. 

Targeting a novel, stress-induced therapeutic intevention point, the company’s current preclinical lead, ATX-101, sensitizes cancer cells to the action of >15 different chemotherapeutic drugs across multiple indications. The company has achieved proof-of-concept in selected in vivo and ex vivo cancer models of solid tumors (e.g. bladder, prostate) and blood cancer (myeloma, leukemia) in combination with >5 clinical drugs. 

APIM Therapeutics is venture capital financed. Current investors include Sarsia Seed, Birk Venture, Ro Invest and NIK. The company is seeking to raise additional funding in 2012-2013 in order to drive continuous preclinical development of ATX-101 to IND within a period of 18 months. 

BerGenBio AS develops novel cancer therapeutics against highly invasive and drug resistant tumors; its R&D is directed towards targeting the tumor microenvironment, EMT and cancer stem cells. Our lead program BGB324 is a first in class Axl inhibitor will enter Ph1 in January 2013 and has shown preclinical activity in many cancers, including AML, NSCLC, breast, pancreatic and melanoma.

The company is built on proprietary state-of-the-art RNAi technology dedicated to identifying and validating novel cancer targets, other programs are in the drug discovery and lead optimization stages.

The company located in Bergen, Norway. It is funded by a syndicate of Norwegian investors and seeking qualified co-investors for a €12m series B at YE 2012.

Bioversys AG is a privately held Swiss biopharmaceutical company located in Basel that focuses on research and development of new drugs and compounds, which switch-off drug resistance within bacterial pathogens and restore the efficacy of approved antibiotics. Spun out of the ETH-Zurich in 2008, we have profound technological expertise that is based on solid IP.

Corporate

• Ceronco Biosciences is developing new drugs to fight cancer based on the short-chain sphingolipid (SCS) technology discovered in a collaborative research project at the Netherlands Cancer Institute (NKI) and Erasmus MC.
• Proof of principle has been established in combining the SCS-technology with doxorubicin in highly relevant animal models. Addition of the SCS leads to increase in uptake of doxorubicin, specifically in cancer cells, and subsequently a significant reduction in tumor growth and increase in overall survival. At the same time no increase in severity of expected side effects or new side effects were noted.
• Ceronco is now taking this first product (CB001) into clinical trials, with expected start of the first clinical trial early 2013.

Technology

• A major barrier for uptake of chemotherapeutic drugs is the cellular membrane of a cancer cell. A new class of short-chain sphingolipids (SCS) has been identified which insert themselves into the cellular membrane and lead to catalysis of drug-membrane translocation. This results in increased uptake of a large variety of amphiphilic chemotherapeutic drugs.
• Tumor Cell Membrane Modulation using the SCS-technology is a novel and unique method to increase the efficacy of chemotherpaeutic drugs.

Products

• CB001: GluCer-enhanced liposomal doxorubicin
• CB002: SCS-enhanced mitoxantrone

eADMET is an expert in the creation of customised computational models for the prediction of ADME/Tox properties of small drug-like molecules. eADMET’s modular approach combines proprietary and selected external algorithms to create customised prediction models (with integrated error estimation) for clients and partners from the pharmaceutical and biotechnology industry.

eADMET’s product portfolio includes:

1. OCHEM - a public accessible reference system and database
2. Validated models for precise prediction of various ADME/Tox parameters
3. User-friendly customized model solutions for specific customer needs
4. Expert consultancy services with respect to model application and interpretations.

New developments include chemogenomic methods and methods for in vitro to in vivo correlations to address toxicity prediction within drug discovery and REACH.

eADMET was founded as a result of GO-Bio project awarded to Dr Tetko with a financial support from High-Tech Gründerfonds (HTGF) and Bayern Kapital. it is a spinout from Helmholtz Centre, Munich.

EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.

EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. Subsequent developments may identify other potential clinical indications outside oncology.

In December 2010, Epitherapeutics signed a drug discovery collaboration with Abbott Laboratories.

Epitherapeutics employs 25 FTE and is headquartered in Copenhagen.

Genticel is a clinical stage biopharmaceutical company that develops multivalent vaccines for patients infected with Human Papillomavirus (HPV). Till date, the company has raised EUR 27 Mio in funding.

Current investors include Edmond de Rothschild Venture Partners, Innobio Fund, IDInvest (Allianz) and Amundi. 

Our lead investigational vaccine, ProCervix, has successfully finished a very positive data-rich Phase Ib trial on 47 HPV16 and/or 18 infected women. ProCervix is the first therapeutic vaccine offering a solution to the more than 93 million women worldwide already infected with HPV 16 and/or 18 before the appearance of high grade neoplasia. This very large population, exposed at high risk to develop cervical cancer, is only now becoming accessible thanks to new screening guidelines prescribing first line HPV-based testing.

A large survey of prescribers and a Market Access Study predict overwhelming acceptability and a very large market potential.

Genticel wants to take ProCervix into Clinical Phase II and further develop our second product, a heptavalent therapeutic HPV vaccine, up to clinical stage.

To do this, we intend to raise additional capital from our current and selected international investors. 

InteRNA Technologies is a Dutch drug discovery and development company engaged in the development of novel breakthrough cancer therapies based on the unique functions of its proprietary miRNAs.

InteRNA well equipped to move quickly towards the clinic

InteRNA's drug development programs aim at developing miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes that are known to play a role in cancer initiation, progression and metastasis.

InteRNA identified the function of multiple miRNAs in a number of cancer indications through functional screens, using its proprietary lentiviral-based miRNA expression library, which is the largest currently available.

With the Company's proprietary miRNA expression database (generated through deep sequencing) and additional technologies (like RNAseq, PAR-CLIP, bioinformatics, in vivo models) in place to identify the downstream regulated proteins for each miRNA drug candidate, the Company is well equipped to move its novel drug candidates with their biomarkers quickly towards the clinic.